Q BioMed Inc.
QBIO · OTC
11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 45.4% | 552% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.2% | -26.2% | -986.7% | – |
| R&D Expenses | $0 | $1 | $2 | $4 |
| G&A Expenses | $3 | $6 | $11 | $4 |
| SG&A Expenses | $3 | $6 | $11 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $7 | $13 | $8 |
| Operating Income | -$3 | -$7 | -$13 | -$8 |
| % Margin | -1,211.7% | -3,777.4% | -43,818% | – |
| Other Income/Exp. Net | $1 | -$1 | -$0 | -$2 |
| Pre-Tax Income | -$2 | -$8 | -$13 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$8 | -$13 | -$10 |
| % Margin | -721.7% | -4,213% | -44,974% | – |
| EPS | -0.078 | -0.33 | -0.65 | -0.78 |
| % Growth | 76.3% | 49.2% | 16.7% | – |
| EPS Diluted | -0.078 | -0.33 | -0.65 | -0.78 |
| Weighted Avg Shares Out | 45 | 27 | 22 | 15 |
| Weighted Avg Shares Out Dil | 45 | 27 | 22 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $1 | $1 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$8 | -$13 | -$8 |
| % Margin | -217.2% | -3,928.3% | -43,819.9% | – |